Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Total Current Liabilities of $499.2 million for Q1 2026, down 17.57% year-over-year from $605.6 million in Q1 2025, and down 54.43% quarter-over-quarter from $1.1 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Total Current Liabilities (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Total Current Liabilities history runs 17 years deep, the most recent figure standing at $499.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities fell 17.57% year-over-year to $499.2 million; the TTM figure through Mar 2026 stood at $499.2 million (down 17.57% YoY), while the FY2025 annual figure was $1.1 billion, up 49.69% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $499.2 million, down from $1.1 billion in the prior quarter.
- The five-year high for Total Current Liabilities was $1.1 billion in Q4 2025, with the low at $450.7 million in Q3 2023.
- The 5-year median for Total Current Liabilities is $608.7 million (2024), against an average of $654.9 million.
- The sharpest annual moves came in 2022 and 2023: Total Current Liabilities soared 61.45% in 2022, then slipped 25.24% in 2023.
- Sarepta Therapeutics' Total Current Liabilities stood at $619.6 million in 2022, then increased by 5.5% to $653.7 million in 2023, then rose by 11.94% to $731.7 million in 2024, then soared by 49.69% to $1.1 billion in 2025, then tumbled by 54.43% to $499.2 million in 2026.
- Business Quant data shows SRPT's Total Current Liabilities at $499.2 million in Q1 2026, $1.1 billion in Q4 2025, and $921.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.58 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 354.06 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 2.12 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4.22 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 630.93 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.51 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 438.74 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 502.91 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 502.91 Mn |
| Mar 31, 2026 | 499.16 Mn |
| Dec 31, 2025 | 1.10 Bn |
| Sep 30, 2025 | 921.43 Mn |
| Jun 30, 2025 | 919.95 Mn |
| Mar 31, 2025 | 605.59 Mn |
| Dec 31, 2024 | 731.68 Mn |
| Sep 30, 2024 | 699.49 Mn |
| Jun 30, 2024 | 688.49 Mn |
| Mar 31, 2024 | 608.71 Mn |
| Dec 31, 2023 | 653.66 Mn |
| Sep 30, 2023 | 450.74 Mn |
| Jun 30, 2023 | 498.65 Mn |
| Mar 31, 2023 | 536.88 Mn |
| Dec 31, 2022 | 619.60 Mn |
| Sep 30, 2022 | 602.92 Mn |
| Jun 30, 2022 | 545.57 Mn |
| Mar 31, 2022 | 454.96 Mn |
| Dec 31, 2021 | 452.73 Mn |
| Sep 30, 2021 | 373.44 Mn |